A one-day IChemE BESIG conference on the newest developments in bioprocessing tools and strategies. Our CEO presents continuous chromatography for biologics — capture and polishing for monoclonal antibodies, bispecifics, and ADCs.
Event at a Glance
| Event | BESIG Novel Technologies in Bioprocessing Conference (IChemE Biochemical Engineering Special Interest Group) |
| Date | Tuesday, 23 June 2026 (one-day conference) |
| Venue | University College London (UCL), London, United Kingdom |
| YMC ChromaCon focus | Continuous chromatography for biologics — CaptureSMB® capture and MCSGP polishing for mAbs, bispecifics, and ADCs |
Our Talk
Continuous Chromatography for Biologics
Tuesday, 23 June 2026 · UCL, London
Dr. Thomas Müller-Späth — CEO and co-founder, ChromaCon AG, a YMC company
Continuous chromatography offers tremendous improvements in throughput and cost for the downstream processing of biologics. This presentation introduces the core principles of continuous chromatography, then works through case studies across monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). It also covers the two factors that determine whether a continuous process is genuinely production-ready: dynamic process control and scale-up.
The talk addresses, in turn:
- Continuous capture for monoclonal antibodies. CaptureSMB® twin-column periodic countercurrent capture loads Protein A resin safely beyond breakthrough, delivering 2.5× higher productivity, 92% resin utilisation, and 50% buffer savings versus batch — validated from lab to GMP scale by Bristol Myers Squibb. AutomAb® dynamic control adjusts loading duration in real time to compensate for feed titer variability and column aging.
- Polishing for bispecifics and ADCs. MCSGP continuous polishing eliminates the purity-yield trade-off of batch chromatography by internally recycling impure side-fractions. For bispecific charge-variant profiles and high-value ADC payloads, AutoPeak® dynamic control keeps the product collection window precisely on target across long campaigns.
- Process control and scale-up. AutomAb® and AutoPeak® — our proprietary UV-based dynamic control technologies — are what take a continuous process from development-ready to production-ready, and are validated as Process Analytical Technology (PAT). Methods transfer directly from the Contichrom® CUBE to GMP manufacturing on the Contichrom® TWIN.
Case Studies at a Glance
| Antibody format | Continuous chromatography approach | What it delivers |
| Monoclonal antibodies | Continuous Protein A capture with CaptureSMB® and AutomAb® dynamic control | 2.5× higher productivity, 92% resin utilisation, 50% less buffer — validated lab-to-GMP by Bristol Myers Squibb |
| Bispecific antibodies | MCSGP continuous polishing with AutoPeak® dynamic control | Resolves complex charge-variant profiles with tight, UV-tracked collection windows |
| ADCs | MCSGP continuous polishing of payloads and conjugates | Recovers high-value product that batch polishing discards; reduces in-process controls and PMI |
Meet Us at UCL
Dr. Thomas Müller-Späth and the YMC ChromaCon team will be available during the conference to discuss:
- Continuous Protein A capture (CaptureSMB®) for mAbs, bispecifics, Fc-fusion proteins, and antibody fragments
- Continuous polishing (MCSGP) for charge variants, aggregates, and ADC payloads
- Dynamic process control with AutomAb® and AutoPeak® — validated as PAT
- Process development on the Contichrom® CUBE and scale-up to GMP manufacturing on the Contichrom® TWIN
- Integration of continuous capture with perfusion bioreactors for end-to-end continuous biomanufacturing
- Feasibility studies, rental options, and on-site demos at our Zurich facility
About the Speaker
Dr. Thomas Müller-Späth is CEO and co-founder of ChromaCon AG, a YMC company, and an expert in downstream processing and continuous bioprocessing technologies, with extensive experience in chromatography process development, scale-up, and manufacturing for biologics. He has led the development of CaptureSMB®, MCSGP, AutomAb®, AutoPeak®, and N-Rich® from research concept to GMP-validated commercial technology.
